Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis

Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell... ORIGINAL ARTICLE Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis Yosuke Togashi, MD,* Katsuhiro Masago, MD, PhD,* Masahide Fukudo, PhD,† Tomohiro Terada, PhD,† Yasuaki Ikemi, BPharm,† Young Hak Kim, MD,* Shiro Fujita, MD, PhD,‡ Kaoru Irisa, MD,* Yuichi Sakamori, MD,* Tadashi Mio, MD, PhD,* Ken-ichi Inui, PhD,† and Michiaki Mishima, MD, PhD* atients with chronic renal failure (CRF) undergoing he- Introduction: Although erlotinib, an orally active and selective Pmodialysis (HD) are potentially at increased risk of cancer tyrosine kinase inhibitor of epidermal growth factor receptor, is for several reasons including the presence of chronic infec- mainly metabolized in the liver, its effectiveness and safety for tion, weakened immune system, nutritional deficiencies, and patients with chronic renal failure (CRF) undergoing hemodialysis altered DNA repair. Although it is uncertain that patients (HD) has not been reported. Thus, we investigated the pharmacoki- with CRF undergoing HD are at risk for lung cancer, more netics (PK) of erlotinib and its active metabolite OSI-420 in such patients undergoing HD will be diagnosed with lung cancer patients with nonsmall cell lung cancer (NSCLC). because recent advances in HD have resulted http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis

Journal of Thoracic Oncology , Volume 5 (5) – May 1, 2010

Loading next page...
 
/lp/wolters-kluwer-health/pharmacokinetics-of-erlotinib-and-its-active-metabolite-osi-420-in-Jj2EAajUiJ

References (17)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181d32287
pmid
20234322
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis Yosuke Togashi, MD,* Katsuhiro Masago, MD, PhD,* Masahide Fukudo, PhD,† Tomohiro Terada, PhD,† Yasuaki Ikemi, BPharm,† Young Hak Kim, MD,* Shiro Fujita, MD, PhD,‡ Kaoru Irisa, MD,* Yuichi Sakamori, MD,* Tadashi Mio, MD, PhD,* Ken-ichi Inui, PhD,† and Michiaki Mishima, MD, PhD* atients with chronic renal failure (CRF) undergoing he- Introduction: Although erlotinib, an orally active and selective Pmodialysis (HD) are potentially at increased risk of cancer tyrosine kinase inhibitor of epidermal growth factor receptor, is for several reasons including the presence of chronic infec- mainly metabolized in the liver, its effectiveness and safety for tion, weakened immune system, nutritional deficiencies, and patients with chronic renal failure (CRF) undergoing hemodialysis altered DNA repair. Although it is uncertain that patients (HD) has not been reported. Thus, we investigated the pharmacoki- with CRF undergoing HD are at risk for lung cancer, more netics (PK) of erlotinib and its active metabolite OSI-420 in such patients undergoing HD will be diagnosed with lung cancer patients with nonsmall cell lung cancer (NSCLC). because recent advances in HD have resulted

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: May 1, 2010

There are no references for this article.